On February 9, 2026, Becton Dickinson completed the spin-off of its Biosciences and Diagnostics Solutions business, merging it with Waters Corporation, and received $4 billion in cash for future share repurchases and debt repayments. Shareholders received approximately 38.5 million shares of Waters stock as part of the transaction.